Primary Hyperoxaluria Epidemiology Forecast

DelveInsight’s ‘Primary Hyperoxaluria- Epidemiology Forecast–2030’ report delivers an in-depth understanding of the Primary Hyperoxaluria historical and forecasted epidemiology as well as the Primary Hyperoxaluria epidemiology trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2018–2030

Primary Hyperoxaluria Understanding

Primary Hyperoxaluria Overview

Primary Hyperoxaluria is a rare genetic disease caused by deficiencies in glyoxylate metabolism. Broadly, the PH is inherited in an autosomal recessive fashion and divided into three types based on the different responsible genes: type 1 (AGXT) (PH-I), type 2 (GRHPR) (PH-II), and type 3 (HOGA1) (PH-III). The kidney is the prime target for oxalate deposition, which leads to end-stage renal disease in a significant number of cases.


Signs and symptoms may include recurrent kidney stones, hematuria, and urinary tract infections (UTIs). Phenotypically the disease is characterized by the recurrent formation of kidney stones and nephrocalcinosis, resulting in the gradual decline of kidney function. Once renal function deteriorates, excessive oxalate can no longer be eliminated through the urine, and thus calcium oxalate crystals precipitate in various tissues, leading to a devastating multiorgan disease called systemic oxalosis.


Primary Hyperoxaluria Diagnosis

Diagnosis of PH is based upon identification of characteristic symptoms (e.g. chronic stone formation), a detailed patient history, a thorough clinical evaluation, and a variety of specialized tests. Children with nephrocalcinosis or kidney stones should be screened for PH. PH may be suspected in individuals with a history of recurrent kidney stones and/or nephrocalcinosis. Because these conditions are rare, there may be a delay from symptom onset to diagnosis. Investigation for PH includes measuring urine and plasma oxalate levels, ruling out other causes of high oxalate levels (dietary or enteric hyperoxaluria), molecular genetic testing for mutations, and detecting the presence of kidney stones and examining their composition.

Primary Hyperoxaluria Epidemiology Perspective by DelveInsight

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Prevalent Cases of Primary Hyperoxaluria, Diagnosed Prevalent Cases of Primary Hyperoxaluria, Gender-specific Diagnosed Prevalent Cases of Primary Hyperoxaluria, Age-specific Diagnosed Prevalent Cases of Primary Hyperoxaluria, and Type-specific Diagnosed Prevalent Cases of Primary Hyperoxaluria scenario in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2018 to 2030.

Primary Hyperoxaluria Detailed Epidemiology Segmentation

  • The total prevalent population of PH in 7MM was 11,918 in 2020, which is expected to increase at a CAGR of 0.78%. However, the majority of the cases remain undiagnosed.
  • The US accounted for the highest prevalent population of PH among 7MM with 8,773 cases in 2020.
  • The estimates suggest a higher diagnosed prevalence of PH in the United States with 2,327 diagnosed cases in 2020.
  • Diagnosed Prevalent population of PH in the US is expected to increase at a CAGR of 3.80% for the study period, i.e. 2018–2030.
  • Age-groups 0–4 years contributed to 29.96% of the total diagnosed prevalent cases of PH in the US, in 2020, followed by age groups 5–9 years.
  • Among the European countries, the UK had the highest diagnosed prevalent population of PH with 198 cases, followed by Germany which had diagnosed prevalent population of 171, in 2020. On the other hand, Spain had the lowest diagnosed prevalent population (95 cases).
  • Epidemiology assessed for PH showed that Japan accounts for approximately 2.57% of the total 7MM diagnosed prevalent population, which approximates 81 cases in 2020.
  • The estimates suggest a higher diagnosed prevalence of PH Type 1 throughout the 7MM. In the US, out of 2,327 diagnosed prevalent cases of PH; 1,629 were of PH Type 1 alone, in the year 2020.
  • In 2020, out of total diagnosed prevalent cases in Japan, males and females contributed to 48 and 33 cases, respectively.

Scope of the Report

  • The report covers the descriptive overview of Primary Hyperoxaluria, explaining its causes, signs, and symptoms, pathophysiology, and diagnosis.
  • The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
  • The report assesses the disease risk and burden.
  • The report provides the segmentation of the disease epidemiology for 7MM by segmented by Prevalent Cases of Primary Hyperoxaluria, Diagnosed Prevalent Cases of Primary Hyperoxaluria, Gender-specific Diagnosed Prevalent Cases of Primary Hyperoxaluria, Age-specific Diagnosed Prevalent Cases of Primary Hyperoxaluria, and Type-specific Diagnosed Prevalent Cases of Primary Hyperoxaluria.

Report Highlights

  • 10-Year Forecast of Primary Hyperoxaluria
  • 7MM Coverage
  • Prevalent Cases of Primary Hyperoxaluria
  • Diagnosed Prevalent Cases of Primary Hyperoxaluria
  • Gender-specific Diagnosed Prevalent Cases of Primary Hyperoxaluria
  • Age-specific Diagnosed Prevalent Cases of Primary Hyperoxaluria
  • Type-specific Diagnosed Prevalent Cases of Primary Hyperoxaluria

Key Questions Answered

  • What are the disease risk, burdens, and unmet needs of Primary Hyperoxaluria?
  • What is the historical Primary Hyperoxaluria patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK), and Japan?
  • What would be the forecasted patient pool of Primary Hyperoxaluria at the 7MM level?
  • What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Primary Hyperoxaluria?
  • Out of the countries mentioned above, which country would have the highest patient population of Primary Hyperoxaluria during the forecast period (2021–2030)?
  • At what CAGR the population is expected to grow across the 7MM during the forecast period (2021–2030)?

Reasons to buy

The Primary Hyperoxaluria report will allow the user to -

  • Develop business strategies by understanding the trends shaping and driving the 7MM Primary Hyperoxaluria epidemiology.
  • Quantify patient populations in the 7MM Primary Hyperoxaluria market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the type-specific cases of Primary Hyperoxaluria that present the best opportunities for Primary Hyperoxaluria therapeutics in each of the markets covered.
  • The Primary Hyperoxaluria epidemiology report and model were written and developed by Masters and PhD level epidemiologists.
  • The Primary Hyperoxaluria epidemiology model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the 10-year forecast period using reputable sources.

Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

1. Key Insights

2. Report Introduction

3. Primary Hyperoxaluria Patient Share Distribution Overview at a Glance

3.1. Patient Share (%) Distribution of Primary Hyperoxaluria in 2018

3.2. Patient Share (%) Distribution of Primary Hyperoxaluria in 2030

4. Executive Summary of Primary Hyperoxaluria

5. Disease Background and Overview

5.1. Introduction

5.2. Classification

5.3. Symptoms

5.4. Genetic Basis of Primary Hyperoxaluria

5.5. Etiology

5.6. Pathophysiology

5.7. Clinical Manifestations

5.8. Diagnosis

5.8.1. Diagnostic Algorithm for Primary Hyperoxaluria

5.8.2. Diagnostic Guidelines

5.8.2.1. Primary Hyperoxaluria Type 1: Indications for Screening and Guidance for Diagnosis

6. Epidemiology and Patient Population

6.1. Key Findings

6.2. Methodology of Epidemiology

6.3. Assumptions and Rationale: 7MM

6.4. Total Prevalent Patient Population of Primary Hyperoxaluria in the 7MM

6.5. Total Diagnosed Prevalent Patient Population of Primary Hyperoxaluria in the 7MM

6.6. The United States

6.6.1. Prevalent Cases of Primary Hyperoxaluria in the United States

6.6.2. Diagnosed Prevalent Cases of Primary Hyperoxaluria in the United States

6.6.3. Gender-specific Diagnosed Prevalent Cases of Primary Hyperoxaluria in the United States

6.6.4. Age-specific Diagnosed Prevalent cases of Primary Hyperoxaluria in the United States

6.6.5. Type-specific Diagnosed Prevalent cases of Primary Hyperoxaluria in the United States

6.7. EU-5

6.7.1. Prevalent Cases of Primary Hyperoxaluria in EU-5

6.7.2. Diagnosed Prevalent Cases of Primary Hyperoxaluria in EU-5

6.7.3. Gender-specific Diagnosed Prevalent Cases of Primary Hyperoxaluria in EU-5

6.7.4. Age-specific Diagnosed Prevalent cases of PH in EU-5

6.7.5. Type-specific Diagnosed Prevalent cases of Primary Hyperoxaluria in EU-5

6.8. Japan

6.8.1. Prevalent Cases of Primary Hyperoxaluria in Japan

6.8.2. Diagnosed Prevalent Cases of Primary Hyperoxaluria in Japan

6.8.3. Gender-specific Diagnosed Prevalent Cases of Primary Hyperoxaluria in Japan

6.8.4. Age-specific Diagnosed Prevalent cases of Primary Hyperoxaluria in Japan

6.8.5. Type-specific Diagnosed Prevalent cases of Primary Hyperoxaluria in Japan

7. KOL Views

7.1. The US KOL Views

7.2. EU5 KOL Views

8. Appendix

8.1. Bibliography

8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

List of Table

Table 1: Summary of PH Epidemiology (2018–2030)

Table 2: Comparison Between Primary and Secondary Hyperoxaluria

Table 3: Comparing the Different Types of Primary Hyperoxaluria

Table 4: Symptoms of PH

Table 5: Characteristics of Infantile Cases of PH-I by Genotype

Table 6: Percentage of the most common mutations identified from 222 alleles

Table 7: Tests for Diagnosing Primary Hyperoxaluria

Table 8: Recommendations

Table 9: Recommendations

Table 10: Total Prevalent Population of Primary Hyperoxaluria in the 7MM (2018–2030)

Table 11: Total Diagnosed Prevalent Population of Primary Hyperoxaluria in the 7MM (2018–2030)

Table 12: Prevalent Cases of Primary Hyperoxaluria in the United States (2018–2030)

Table 13: Diagnosed Prevalent Cases of Primary Hyperoxaluria in the US (2018–2030)

Table 14: Gender-specific Diagnosed Prevalent Cases of Primary Hyperoxaluria in the US (2018–2030)

Table 15: Age-specific Diagnosed Prevalent Cases of Primary Hyperoxaluria in the US (2018–2030)

Table 16: Type-specific Diagnosed Prevalent Cases of Primary Hyperoxaluria in the US (2018–2030)

Table 17: Prevalent Cases of Primary Hyperoxaluria in EU-5 (2018–2030)

Table 18: Diagnosed Prevalent Cases of Primary Hyperoxaluria in EU-5 (2018–2030)

Table 19: Gender-specific Diagnosed Prevalent Cases of Primary Hyperoxaluria in EU-5 (2018–2030)

Table 20: Age-specific Diagnosed Prevalent Cases of Primary Hyperoxaluria in EU5 (2018–2030)

Table 21: Type-specific Diagnosed Prevalent Cases of Primary Hyperoxaluria in EU5 (2018–2030)

Table 22: Prevalent Cases of Primary Hyperoxaluria in Japan (2018–2030)

Table 23: Diagnosed Prevalent Cases of Primary Hyperoxaluria in Japan (2018–2030)

Table 24: Gender-specific Diagnosed Prevalent Cases of Primary Hyperoxaluria in Japan (2018–2030)

Table 25: Age-specific Diagnosed Prevalent cases of Primary Hyperoxaluria in Japan (2018–2030)

Table 26: Type-specific Diagnosed Prevalent cases of Primary Hyperoxaluria in Japan (2018–2030)

List of Figures

Figure 1: Calcium Oxalate Deposits in the Urinary Space and in the Renal Tissue

Figure 2: Bone Oxalosis

Figure 3: Subtypes Of Primary Hyperoxaluria

Figure 4: Symptoms Onset and Age at Diagnosis of PH

Figure 5: Main Routes of Glyoxalate Metabolism in a Human Hepatocyte

Figure 6: Factors Potentially Influencing the Metabolism of Oxalate and Renal Outcome in Patients With PH-I

Figure 7: Diagnosis of Primary Hyperoxaluria

Figure 8: Total Prevalent Patient Population of Primary Hyperoxaluria in the 7MM (2018–2030)

Figure 9: Total Diagnosed Prevalent Patient Population of Primary Hyperoxaluria in the 7MM (2018–2030)

Figure 10: Prevalent Cases of Primary Hyperoxaluria in the United States (2018–2030)

Figure 11: Diagnosed Prevalent Cases of Primary Hyperoxaluria in the US (2018–2030)

Figure 12: Gender-specific Diagnosed Prevalent Cases of Primary Hyperoxaluria in the US (2018–2030)

Figure 13: Age-specific Diagnosed prevalent Cases of Primary Hyperoxaluria in the US (2018–2030)

Figure 14: Type-specific Diagnosed Prevalent Cases of Primary Hyperoxaluria in the US (2018–2030)

Figure 15: Prevalent Cases of Primary Hyperoxaluria in EU-5 (2018–2030)

Figure 16: Diagnosed Prevalent Cases of Primary Hyperoxaluria in EU-5 (2018–2030)

Figure 17: Gender-specific Diagnosed Prevalent Cases of Primary Hyperoxaluria in EU-5 (2018–2030)

Figure 18: Age-specific Diagnosed Prevalent cases of Primary Hyperoxaluria in EU-5

Figure 19: Type-specific Diagnosed Prevalent cases of Primary Hyperoxaluria in EU-5

Figure 20: Prevalent Cases of Primary Hyperoxaluria in Japan (2018–2030)

Figure 21: Diagnosed Prevalent Cases of Primary Hyperoxaluria in Japan (2018–2030)

Figure 22: Gender-specific Diagnosed Prevalent Cases of Primary Hyperoxaluria in Japan (2018–2030)

Figure 23: Age-specific Diagnosed Prevalent cases of Primary Hyperoxaluria in Japan (2018–2030)

Figure 24: Type-specific Diagnosed Prevalent cases of Primary Hyperoxaluria in Japan (2018–2030)

  • Tags:
  • Primary Hyperoxaluria Epidemiology
  • Primary Hyperoxaluria
  • Primary Hyperoxaluria Pipeline
  • Primary Hyperoxaluria Companies
  • Primary Hyperoxaluria prevalent po...
  • Primary Hyperoxaluria incident pop...
  • Primary Hyperoxaluria patients dia...
  • Primary Hyperoxaluria treatment al...

Forward to Friend

Need A Quote